

Rec'd PC TO 18 FEB 2005 #2

PCT/GB 2003 / 0 0 3 6 4 9



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport

South Wales
NP10 8QQ 23 SEP 2003

WIPO PCT

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Andrew Gersey

Dated

10 September 2003



Patents Form 1/77

Patents Act 1977
(Rule 16)



21 AUG 02 1742478-9-000192
POL/7700 8:00-0219409-1

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference N.86431 PEJ

2. Patent application number
(The Patent Office will fill in this part)

0219409.0

20 AUG 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

OXONICA LIMITED

Unit 7 BEGBROKE SCIENCE + BUSINESS
PARK,
SANDY LAKE, YARNTON,
KIDLINGTON, OXFORD OX5 1PF
8147845001

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

British body corporate

4. Title of the invention

LUMINESCENT COMPOUNDS

5. Name of your agent (if you have one)

J.A. KEMP & CO.

"Address for service" in the United Kingdom to which all correspondence should be sent (Including the postcode)

14 South Square
Gray's Inn
London
WC1R 5JJ

26001

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

9. Enter the number of sheets for any one of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	8
Claim(s)	3
Abstract	1
Drawing(s)	2 <i>12</i>

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) 1

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

J.A. Kemp
J.A. KEMP & CO.

Date 20 August 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

PGA Ellis-Jones
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*


LUMINESCENT COMPOUNDS

5 This invention relates to luminescent compounds that will absorb in the near UV (defined at least 300nm) and emit in the visible. Such compounds are of potential use as luminescent tags in a biological diagnostic system or in luminescent security tags.

10 Most conventional phosphor materials are excited by 200-300nm UV. This makes such materials of little use for biotagging purposes because these wavelengths are strongly absorbed by biological molecules such as DNA. Accordingly, there is a real need for luminescent centres that excite in the near UV and/or short wavelength blue and which can, nevertheless, be used in biotagging purposes. Excitations from greater than 300 to 400 nm are therefore preferred. In addition, materials which have
15 the potential of being used as a biotag must fully disperse in water and be capable of being incorporated in, typically, silica spheres or other surface coatings which enable them to be attached to the biological molecule. Unfortunately, known materials of rare earth elements such as europium, while absorbing in the near UV and emitting in the visible, are quenched in water via a de-excitation state via a hydroxyl ion. This is
20 a non-radiative effect with the result that the known materials cannot be used for this purpose.

 According to the present invention it has surprisingly been found that it is possible to produce luminescent material derived from polyoxo/thioimmetallates which can coordinate with luminescent centres such as lanthanides such that efficient
25 luminescence can be pumped from the near UV.

 According to the present invention there is provided a luminescent particle comprising one or more compounds of the formula:



30

wherein:

M^2 is a cation, generally an ion of hydrogen or a metal of group 1A or 2A of the Periodic Table or an optionally substituted ammonium ion, or a mixture of two or more said ions,

M^1 is an ion of a metal capable of providing a luminescent centre or a mixture of two

5 or more thereof, and

POM is a polyoxometallate, a polythiometallate or a polyoxythiometallate (optionally having a hetero atom X as explained below) of at least one metal of group VA or VIA of the Periodic Table, the amounts of X, M^1 , M^2 and POM being such as to provide overall neutrality.

10 Where a particle contains more than one such compound, then the different compounds thereof may differ in any one or more of the M^2 , M^1 , POM or X that they contain. The particles may consist primarily of (i.e. at least 50% by weight of), and preferably consist substantially entirely of (say at least 95% by weight of), the compounds defined above. However, where other materials are present, those other
15 materials may comprises one or more other phosphors. Also, the present particles may be mixed with or otherwise used in conjunction with particles of other phosphors. This can result in a combination of, say, green and red emissions.

Metals of group V and VI of the Periodic Table, (see Chemistry of the Elements, Greenwood & Earnshaw, Pergamon, 1984), notably vanadium, niobium,
20 tantalum, molybdenum and tungsten, are able to form, in their highest oxidation state, metal oxygen/sulphur cluster ions known as polyoxo/thiometallates, and are collectively referred to herein for convenience as "POM". The invention will be discussed principally in terms of oxo embodiments but it is to be understood that the comments made apply also to the thio and mixed embodiments. The majority of
25 structures are constructed from these transition metals as polyhedrons and may be viewed as arrangements of edge and vertex sharing MO_6 octahedra and have one or two terminal oxygen ions although other polyhedral structures can be formed. At present we prefer POM structures that are symmetrical. It is believed that these POM have a crystal structure which excludes water ions from the inner coordination shell
30 of the emitting ion and which effectively protects europium or other lanthanides from

water such that the compounds are not quenched by water.

M^2 can generally be any cation which does not interfere with the luminescence of the particle. Therefore it should not be an M^1 metal and generally not a transition metal. It is typically an ion of hydrogen or group IA or IIA of the Periodic Table or an optionally substituted ammonium ion. Typically, M^2 is potassium or sodium or NH_4 . However, the ammonium ion may be substituted by, for example, aliphatic or aromatic groups, typically alkyl groups of 1 to 6 carbon atoms such as methyl, ethyl, propyl or butyl and phenyl. All four hydrogen atoms can be replaced by substituents or 1, 2 or 3 hydrogen atoms can remain. A typical organic counterion is tetrabutyl ammonium. M^2 does not play an active role in the luminescence and acts as a counterion for the remainder of the molecule.

As indicated, M^1 is a metal capable of providing a luminescent centre and is typically a lanthanide although other metals include chromium, titanium and manganese can also be used. Typical ions include Eu^{3+} , Tb^{3+} , Dy^{3+} , Tm^{3+} , Er^{3+} , Cr^{3+} , Ce^{3+} , Pr^{3+} , Sm^{3+} , Nd^{3+} , Ho^{3+} , Yb^{3+} , Ti^{4+} , Mn^{2+} and Mn^{4+} . Preferred ions include Eu^{3+} , Tb^{3+} and Dy^{3+} . In this connection it should be pointed out that, europium, in particular, has in the past been incorporated in POMs but this has been for the purpose of examining crystal structure. In other words there has been no suggestion that the compounds could be used in biotagging or other such applications.

POM is a polyoxo/thiometallate of a group V or group VI metal, in particular vanadium, niobium, tantalum, molybdenum and tungsten, the last two being particularly preferred.

As indicated above, the crystal structure of the POM is particularly important in providing a "shield" for the luminescent centre which is incorporated in it. In addition, in order to maintain a high quantum efficiency, energy transfer from charge transfer state to the optically active centre must be efficient. This is believed to be governed by the de-localisation of the electron wave function over the POM structure and this is in turn governed by the M-O-M or M-S-M bond angles. It has been found that this structure can be modified by incorporation of a "heteroelement" X in the POM, where X is for example a transition metal or an element such as B, Al, Si, P, S,

Ga, Ge, As, Se, In, Sb, Te, I, Pb or Bi. The use of Si or Al is particularly preferred. The precise nature of the heteroelement is generally unimportant provided that it will form O-M-O-X- linkages.

It is believed that the nature of M governs the absorption wavelength of the light while, of course, M^1 governs the emission. As previously indicated, the heteroelement X can have an effect on the bond angles i.e. the structure which is important for the delocalisation of an electron. It is believed that X does not in itself govern either luminescence or emission.

It is a particular feature of polyoxo/thiometallates that they are frequently formed from more than one metal. Typically M is a mixture, for example of molybdenum and tungsten. Also the number of oxygen atoms which are included in the structure frequently exceeds 10 and is typically 15 to 50. Examples include $M_{10}O_{36}$, M_6O_{18} and $M_{11}O_{39}$; of course the number of oxygen atoms is affected by M^1 and X.

It is a further surprising feature of the present invention that the resulting particles possess a high quantum efficiency which is maintained in aqueous solution as well as in the dry state. In general, the particles will possess a quantum efficiency of at least 1%, preferably at least 5%, more preferably at least 20% and especially at least 35%.

The particles of the present invention can generally readily be made by a self-assembly procedure in an acidified medium. They can generally be prepared by mixing a water soluble source of M^2 with a water soluble salt of oxo/thiometallate in water or an aqueous solution. Acid, such as hydrochloric or acetic acid, is then added and then generally heated, typically to a temperature of 80° to 90°C. Generally the pH of the solution will be 8 to 9 and this is reduced to, say, 6.5 to 7.5 by the acid. In general, the degree of acidification affects the final structure of the compounds. If a strong acid is added too quickly to produce a pH of less than 3 locally, then this generates product that is non-luminescent. Finally, a water soluble salt of the metal capable of providing the luminescent centre is added, typically as a halide, for example chloride, which is preferred, or nitrate. This generally results in a

precipitate enabling the particles to be recovered. Sometimes the precipitate dissolves on stirring. The resulting solution, optionally filtered, can then be cooled to cause the desired product to crystallise.

It has been found that it is generally better to use the same cation for the
5 ingredients as that of the desired M^2 .

It is also possible to form oxo/thiometallate by a solid state reaction, for example by high temperature firing, and to form the final lanthanide-activated compound by reaction with the complex lanthanide at neutral or basic pH.

Monomeric oxometallates such as WO_4^{2-} , and MoO_4^{2-} condense in an
10 aqueous acidic media. As there are no electrons available from metallic bonding (due to the maximum valency state of the M ions) the materials are generally held together by closed loops of -O-M-O-M-O- linkages. The structure of the final material is governed by the reaction conditions, principally pH, temperature and the ratio of the reactants. In general, it is recognised that the reactants should be added in
15 the molar proportions that are required in the final product.

If it is desired to incorporate a heteroelement X then this is conveniently added, typically as an oxyanion, for example a silicate, as a water soluble salt. It can generally be added before or after acidification. As well as acidification it has been found that the addition of the heteroelement changes the bond angles and hence the
20 structure of the final product.

Accordingly, the present invention also provides a process for preparing a luminescent particle of the present invention which comprises dissolving a salt of an oxo/thiometallate of M in water together with a water soluble salt of M^2 , adding acid to the resulting solution, subsequently adding a water soluble salt of M^1 and
25 recovering the resulting product, a water soluble salt of an oxo/thioanion of X optionally being added prior to the addition of acid.

The particles obtained by the process typically possess a particle size not exceeding 20 nm, desirably not exceeding 10 nm, preferably not exceeding 5 nm and more preferably not exceeding 2 nm. These sizes are diameters and they assume the
30 particles to be spherical. The particles will in fact usually be substantially spherical;

and when they are not spherical the size is to be taken as the diameter of a sphere of the same volume as that of the actual particle.

The luminescent particles of the present invention find utility in a variety of ways including biotags, drug discovery/development, electroluminescent displays, both AC and DC, magnetic centres of coatings, security marking /labelling/identification, drug delivery and non destructive testing including crack detection as well as in agriculture products. For these purposes they can be delivered by, for example, inkjet, screen printing, injection, dipcoating, or spin coating.

As indicated, the particles of the present invention are particularly useful as phosphors in electroluminescent displays, both AC and DC.

The phosphors also find particular utility in security marking. For this purpose, the phosphors are dispersed in a suitable ink formulation. Typically such formulations involve a binder with the particles. Suitable binders include polymers and resins such as carboxylated acrylic resins and ethylene/vinyl ester copolymers e.g. ethylene/vinyl acetate copolymers e.g. containing about 40% vinyl acetate by weight.

Although it is believed that the particles can sometimes be used as they are for (for example) biotagging and other diagnostic purposes they are typically coated with silica or other material such as titania or zirconia to which an intermediate "biological" molecule can be attached. Alternatively the particles can be capped with an organic acid or Lewis base so that the surface of the particles possesses one or more reactive groups to which a ligand can be attached, the ligand possessing a free reactive group allowing attachment to a biological moiety. Typically ligands which can achieve this include phosphines, phosphine oxides, thiols, amines, carboxylic acids, phosphates, sulfonic acids, sulfinic acids, phosphoric acids, phosphonic acids, phosphinic acids, crown ethers and mixtures of these.

The ligand itself can be monodentate (i.e. with a single binding point, e.g. a trialkylphosphine oxide e.g. with a chain length of 4 to 20 carbon atoms), bidentate (e.g. dihydrolipoic or a dialkyl sulphosuccinate e.g. sodium dioctyl sulphosuccinate with a similar chain length to monodentate) or multi dentate (polymer/dendrimers

with pendant side groups such as phosphines, phosphine oxides, thiols, amines, carboxylic acids, phosphates, sulfonic acids, sulfinic acids, phosphoric acids, phosphinic acids and mixtures). The ligand can also be polymeric i.e. a polymer possessing the desired groups. Typically, therefore, copolymers can be used derived from, for example, a vinyl carboxylic acid such as acrylic acid and a vinyl monomer possessing a group capable of binding to the particles such as vinyl phosphonic acid. For some purposes organic and/or polymeric coatings as well as polyelectrolyte coatings can be provided.

The following Examples further illustrate the present invention.

10

Example 1



0.025M NaWO_4 are dissolved in deionised water, the pH being >8 . The pH is adjusted to 6.5-7.5 with glacial acetic acid at $T > 80^\circ\text{C}$ (typically $85-90^\circ\text{C}$). To this is added 0.0035M DyCl_3 under vigorous stirring. A precipitation occurs, which substantially disappears with continued stirring at $T > 80^\circ\text{C}$. The remaining precipitated material is removed by filtration. The resulting material is filtered once again and the solution is placed at $T > 5^\circ\text{C}$ whereupon crystallisation occurs. These crystals are washed with ethanol and recrystallised from hot water. The crystals are then dried in air at room temperature.

20

This preparation may also be undertaken with Sm instead of Dy to get an orange emitter.

Decay time of emission measured in solid form was of the order of 1.8 ms. By comparison, when the article was dissolved in water, the decay time was about 2.0 ms. This shows that decay time is similar whether the material is in solid form or in water.

25

Example 2

30



$(\text{NH}_4)_3[\text{Al}(\text{OH})_6\text{Mo}_6\text{O}_{18}] \cdot x\text{H}_2\text{O}$ was prepared by mixing sodium molybdate ($2.96 \times 10^{-2}\text{M}$) with $\text{Al}_2(\text{SO}_4)_3$ ($2.47 \times 10^{-3}\text{M}$) at pH 6 to 7 (altered using acetic acid), followed by refluxing for 30 minutes. Any precipitates were removed by filtration.

- 5 An excess of NH_4Cl was then added to the solution, forming a white precipitate, which was isolated by filtration. The solid was then dissolved in hot water and left to crystallize at 0 degrees Celsius. $0.01\text{M} (\text{NH}_4)_3[\text{Al}(\text{OH})_6\text{Mo}_6\text{O}_{18}] \cdot x\text{H}_2\text{O}$ is dissolved in hot deionised water. To this is added an equimolar amount of TbCl_3 with continuous stirring. The reaction was stirred for 30 minutes then reduced in vacuo to
10 a powder.

Example 3



- Sodium tungstate dihydrate (3g, $9.09 \times 10^{-3}\text{M}$), sodium metasilicate (0.19g, $9.09 \times 10^{-4}\text{M}$) and sodium molybdate (0.18g, $9.09 \times 10^{-4}\text{M}$) were dispersed in 5ml 3M
15 NaCl and heated in water bath ($80-90^\circ\text{C}$) until dissolved. To this was added a mixture of 1ml 37% HCl and 1ml H_2O . An initial clouding and pale green precipitate formed, but re-dissolved upon mixing in the water bath. A slight cloudiness persisted, but this was not removed by filtration. To this solution was added $\text{EuNO}_3 \cdot 5\text{H}_2\text{O}$ (0.19g, $4.54 \times 10^{-4}\text{M}$) in 2ml H_2O , whilst stirring in a water bath. An immediate
20 precipitate formed. The reaction was stopped after 1-2 minutes and allowed to cool, and the precipitate was removed by centrifugation. The clear aqueous solution luminesces under 340nm excitation and emits as two peaks in the red at 592nm and 613nm as shown in Figure 2. The solid form of the material is also strongly
25 luminescent.


The mean particle size was about 1.5 nm.

Comparison of the quantum efficiency of the solid form of (1) with a commercial $\text{Y}_2\text{O}_3:\text{Eu}$ phosphor (known efficiency of 70%) shows that the quantum efficiency of the material is 33%. This is shown in Figure 1.

CLAIMS

1. A luminescent particle comprising one or more compounds of the formula:

5



wherein:

M^2 is a cation, M^1 is an ion of a metal capable of providing a luminescent centre or a mixture of two or more thereof, and

10

POM is a polyoxometallate, a polythiometallate or a polyoxythiometallate of at least one metal of group VA or VIA of the Periodic Table and, optionally, a hetero atom X, the amounts of X, M^1 , M^2 and POM being such as to provide overall neutrality.

2. A particle according to claim 1 wherein M^1 is Eu^{3+} , Tb^{3+} , Dy^{3+} , Tm^{3+} , Er^{3+} , Cr^{3+} , Ce^{3+} , Pr^{3+} , Sm^{3+} , Nd^{3+} , Ho^{3+} , Yb^{3+} , Ti^{4+} or Mn^{2+} .

15

3. A particle according to claim 2 wherein M^1 is Dy^{3+} , Eu^{3+} or Tb^{3+} .

4. A particle according to any one of the preceding claims wherein M is vanadium, niobium, tantalum, molybdenum or tungsten.

5. A particle according to claim 4 wherein M is molybdenum or tungsten.

20

6. A particle according to any one of the preceding claims wherein POM contains a heteroelement X.

7. A particle according to claim 6 wherein X is a transition metal or B, Al, Si, P, S, Ga, Ge, As, Se, In, Sb, Te, I, Pb or Bi.

8. A particle according to claim 7 wherein X is Si or Al.

25

9. A particle according to any one of the preceding claims in which the polyoxymetallate comprises MO_6 octahedra.

10. A particle according to any one of the preceding claims wherein M represents more than one metal.

11. A particle according to any one of the preceding claims wherein the

30

compound contains at least 15 oxygen atoms.

12. A particle according to any one of the preceding claims having a quantum efficiency that is at least 1%.

13. A particle according to claim 12 wherein the quantum efficiency is at least 5%.

14. A particle according to any one of the preceding claims wherein M^2 is an ion of hydrogen or a metal of group 1A or 2A of the Periodic Table or an optionally substituted ammonium ion, or a mixture of two or more said ions.

15. A particle according to claim 14 wherein M^2 is sodium, potassium or optionally substituted ammonium.

16. A particle according to claim 15 wherein M^2 is sodium or ammonium.

17. A particle according to any one of the preceding claims which has a diameter not exceeding 20 nm.

18. A particle according to claim 17 which has a diameter not exceeding 5 nm.

19. A particle according to any one of the preceding claims which possesses a coating rendering the particle suitable for biotagging application.

20. A particle according to claim 19 wherein the coating is of silica.

21. A particle according to claim 1 substantially hereinbefore described.

22. A process for preparing a particle as claimed in any one of the preceding claims which comprises dissolving a water soluble salt of an oxo/thiometallate of M and optionally of an oxo/thioanion of X and a water soluble salt of M^2 in water, adding acid, and then adding a water soluble salt of M^1 and recovering the resulting product.

23. A process according to claim 22 wherein the salts are all of M^2 .

24. A process according to claim 22 or 23 wherein the acid is acetic acid or hydrochloric acid.

25. A process according to any one of claims 22 to 24 wherein the mixture is heated before the acid is added.

26. A process according to any one of claims 22 to 25 wherein a water

soluble salt of an oxo/thio anion of X is added with the water soluble salt of the oxo/thiometallate of M.


27. A process according to claim 22 substantially as described in any one of the Examples.

- 5 28. A particle as claimed in any of claims 1 to 21 for use in biotagging, drug discovery/development, electroluminescent displays, magnetic centres of coatings, security marking/labelling/identification, drug delivery, non-destructive testing or in agricultural products.

ABSTRACT

A luminescent particle is described having the formula:

5



wherein:

- M^2 is a cation, M^1 is an ion of a metal capable of providing a luminescent centre or a mixture of two or more thereof, and
- 10 POM is a polyoxometallate, polythiometallate or polyoxothiometallate of at least one metal of group VA or VIA of the Periodic Table and, optionally, a hetero atom, X, the amounts of X, M^1 , M^2 and POM being such as to provide overall neutrality.

1/2

5

10

15

20

25

30





FIGURE 1

2/2

5



10

FIGURE 2

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.